MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis

Company Overview

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Key Stats

• Today's Range: $0.96 to $1.02
• 50-Day Range: $0.95 to $1.16
• 52-Week Range: $0.90 to $2.45
• Volume: 103,646 shs
• Average Volume: 135,706 shs
• Market Capitalization: $41.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

MIRA Pharmaceuticals Stock Analysis - MarketRank™

MIRA Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat, and ranked 806th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

MIRA Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

MIRA Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of MIRA Pharmaceuticals is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MIRA Pharmaceuticals is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MIRA Pharmaceuticals has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.94% of the float of MIRA Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

MIRA Pharmaceuticals has a short interest ratio ("days to cover") of 2.28, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MIRA Pharmaceuticals has recently decreased by 9.76%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MIRA Pharmaceuticals does not currently pay a dividend.

Dividend Growth

MIRA Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.47

News Sentiment

MIRA Pharmaceuticals has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for MIRA Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

4 people have searched for MIRA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.65% of the stock of MIRA Pharmaceuticals is held by insiders.

Percentage Held by Institutions

35.16% of the stock of MIRA Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MIRA
• Previous Symbol: NASDAQ:MIRA
• CIK: 1904286
• Web: mirapharmaceuticals.com
• Phone: 737-289-0835
• Fax: N/A
• Employees: 2
• Year Founded: 1978

Profitability

• EPS (Trailing Twelve Months): ($1.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -140.82%
• Return on Assets: -135.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 82.15
• Quick Ratio: 82.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.25 per share
• Price / Book: 3.91

Miscellaneous

• Outstanding Shares: 42,020,000
• Free Float: 39,228,000
• Market Cap: $41.04 million
• Optionable: Not Optionable
• Beta: 1.43